Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A 6th View: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)

Ticker(s): GBT, Emmaus Life Sciences

Who's the expert?

Name: Dr Alan R. Cohen - MD

Institution: Children's Hospital of Philadelphia

  • Professor of Pediatrics at the Perelman School of Medicine, University of Pennsylvania (Penn) and the Children’s Hospital of Philadelphia (CHOP).
  • Currently manages 30 patients with sickle cell disease.
  • Research interests have focused on thalassemia, sickle cell disease, and transfusional iron overload; he has developed novel approaches to transfusion therapy to reduce the rate of iron accumulation, has led clinical trials of the currently licensed iron chelators, and more than 100 publications are original papers in major journals such as NEJM.

Interview Questions
Q1.

Please describe your background and experience with Sickle Cell Disease and any work with Voxelotor.

Added By: c_admin
Q2.

What is your high level opinion of today's top-line HOPE trial data?

Added By: c_admin
Q3.

On a scale of 1-10 how excited about this program are you for patients?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.